Expression of vascular endothelial growth factors A and C in human pancreatic cancer

Figure 1 Expression of VEGF-A (A) and VEGF-C (B) in six human pancreatic cancer cell lines. Lane 1: COLO-357; lane 2: MIA-PaCa-2; leane 3: PANC-1; lane 4: T3M4; lane 5: ASPC-1; lane 6: CAPAN-1.

Figure 2 Northern blot analysis of VEGF-A and VEGF-C expression in human pancreatic tissues.

Figure 3 Immunohistochemical analysis of VEGF-A (A) and VEGF-C (B) expression in human pancreatic cancer tissues. In the pancreatic cancers, moderate to strong VEGF-A and VEGF-C immunoreactivity was present in the cytoplasm of cancer cells, ×400.

Figure 4 Survival curve. A: Cumulative survival (Kaplan-Meier) plot of the postoperative survival period of patients whose pancreatic tumors exhibited cytoplasmic VEGF-A immunostaining (solid line) versus those whose tumors were negative for VEGF-A (broken line), (P = 0.184); B: Cumulative survival (Kaplan-Meier) plot of the postoperative survival period of patients whose pancreatic tumors exhibited cytoplasmic VEGF-C immunostaining (solid line) versus those whose tumors were negative for VEGF-C (broken line), (P = 0.159).